{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:17:55Z","timestamp":1769069875327,"version":"3.49.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The increased number of effective therapies and the wider use of combinations that give deeper remissions have resulted in a reassessment of the goals of myeloma therapy. With the advent of new therapeutic strategies and diagnostic tools, achievement of minimal residual disease (MRD)-negative status has become increasingly important, with some even considering it as the primary endpoint for therapy. The level of MRD that is aimed for is a continuous, rather than an absolute variable, with studies in both transplant-eligible and -noneligible patients showing that the level of MRD achieved is predictive of progression-free survival and overall survival, with an improvement in survival of approximately 1 year for each log-depletion in MRD level. The most widely used methods to assess MRD status include flow cytometry and clonality detection, using next-generation sequencing technologies with sensitivity limits of 1:10\u22123 to 1:10\u22126. The timing of when to assess MRD depends on the treatment used, as well as the molecular and cytogenetic subgroup of the myeloma itself. It is also becoming clear that the level of MRD negativity, as well as microenvironmental factors, are important prognostically, including the regeneration of normal plasma cells, and the normalization of the immune repertoire. With advances in antibody-based therapy and immunotherapy, the achievement of stable MRD states is now possible for a significant proportion of patients, and is a prerequisite for myeloma cure.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.205","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"205-211","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Is molecular remission the goal of multiple myeloma therapy?"],"prefix":"10.1182","volume":"2017","author":[{"given":"Faith E.","family":"Davies","sequence":"first","affiliation":[{"name":"Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"20","key":"2019111704112120000_B1","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111704112120000_B2","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15","key":"2019111704112120000_B3","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1158\/1078-0432.CCR-16-2895","article-title":"The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications","volume":"23","author":"Anderson","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2019111704112120000_B4","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma [published online ahead of print 10 March 2017]","volume-title":"Leukemia","author":"Flores-Montero"},{"issue":"12","key":"2019111704112120000_B5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"issue":"12","key":"2019111704112120000_B6","doi-asserted-by":"crossref","first-page":"E502","DOI":"10.1002\/ajh.24540","article-title":"Myeloma minimal residual disease testing in the United States: Evidence of improved standardization","volume":"91","author":"Salem","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111704112120000_B7","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"2019111704112120000_B8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111704112120000_B9","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","article-title":"Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction","volume":"125","author":"Rawstron","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2019111704112120000_B10","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111704112120000_B11","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1200\/JCO.2010.33.1967","article-title":"Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma","volume":"29","author":"Paiva","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111704112120000_B12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bbmt.2011.07.002","article-title":"The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter","volume":"18","author":"Korthals","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111704112120000_B13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2019111704112120000_B14","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111704112120000_B15","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111704112120000_B16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2013.217","article-title":"Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry","volume":"28","author":"Puig","year":"2014","journal-title":"Leukemia"},{"issue":"25","key":"2019111704112120000_B17","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du My\u00e9lome","volume":"32","author":"Roussel","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111704112120000_B18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2014.219","article-title":"Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics\u2019 impact on survival","volume":"29","author":"Ferrero","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"2019111704112120000_B19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"issue":"3","key":"2019111704112120000_B20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bjh.13582","article-title":"Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up","volume":"171","author":"Ludwig","year":"2015","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111704112120000_B21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.246.246","article-title":"Evaluation of minimal residual disease (MRD) in relapsed\/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111704112120000_B22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4409.4409","article-title":"Prognostic impact of minimal residual disease by ASO-RQ-PCR in multiple myeloma: a pooled analysis of 2 phase III studies in patients treated with lenalidomide after front-line therapy","volume":"128","author":"Oliva","year":"2016","journal-title":"Blood"},{"issue":"25","key":"2019111704112120000_B23","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111704112120000_B24","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.245.245","article-title":"Impact of minimal residual disease in transplant ineligible myeloma patients: results from the UK NCRI Myeloma XI trials","volume":"128","author":"de Tute","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2019111704112120000_B25","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111704112120000_B26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"12","key":"2019111704112120000_B27","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"2019111704112120000_B28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.191.191","article-title":"Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM\/DFCI 2009 trial","volume":"126","author":"Avet-Loiseau","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111704112120000_B29","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.3324\/haematol.2015.128215","article-title":"Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen","volume":"101","author":"de Tute","year":"2016","journal-title":"Haematologica"},{"issue":"23","key":"2019111704112120000_B30","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R): updated results of a phase 2 study","volume":"128","author":"Kazandjian","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111704112120000_B31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2015.309","article-title":"Clinical value of molecular subtyping multiple myeloma using gene expression profiling","volume":"30","author":"Weinhold","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"2019111704112120000_B32","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.3324\/haematol.2017.165217","article-title":"The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype","volume":"102","author":"Schinke","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"2019111704112120000_B33","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2019111704112120000_B34","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.bbmt.2017.01.076","article-title":"Impact of post-transplant response and minimal residual disease on survival in myeloma with high-risk cytogenetics","volume":"23","author":"Chakraborty","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2019111704112120000_B35","article-title":"Next generation sequencing (NGS) based minimal residual disease (MRD) testing is highly predictive of overall and progression free survival in the Total Therapy trials and shows different prognostic implications in high vs standard risk multiple myeloma","volume":"128","author":"Schinke","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2019111704112120000_B36","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.bbmt.2013.04.025","article-title":"Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma","volume":"19","author":"Korthals","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111704112120000_B37","doi-asserted-by":"crossref","first-page":"15086","DOI":"10.1038\/ncomms15086","article-title":"Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates","volume":"8","author":"Kis","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2019111704112120000_B38","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.celrep.2017.03.025","article-title":"The mutational landscape of circulating tumor cells in multiple myeloma","volume":"19","author":"Mishima","year":"2017","journal-title":"Cell Reports"},{"issue":"23","key":"2019111704112120000_B39","article-title":"Next-generation sequencing based minimal residual disease assessment in peripheral blood RNA from multiple myeloma patients","volume":"128","author":"Wolf","year":"2016","journal-title":"Blood"},{"issue":"389","key":"2019111704112120000_B40","doi-asserted-by":"crossref","first-page":"eaal2668","DOI":"10.1126\/scitranslmed.aal2668","article-title":"Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma","volume":"9","author":"Manier","year":"2017","journal-title":"Sci Transl Med"},{"issue":"15","key":"2019111704112120000_B41","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood-2015-08-665679","article-title":"Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111704112120000_B42","article-title":"Peripheral immune profile and minimal residual disease (MRD) burden following autologous stem cell transplantation (ASCT) in multiple myeloma (MM)","volume":"128","author":"Foureau","year":"2016","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/205\/1249560\/hem00028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/205\/1249560\/hem00028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T04:11:41Z","timestamp":1573963901000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/205\/21038\/Is-molecular-remission-the-goal-of-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.205","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}